From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated glucose blood levels are the key criteria for diagnosing diabetes mellitus (DM). Hyperglycaemia contributes to the pathophysiology associated with DM, including microvascular and possibly macrovascular disease. In spite of a wide range of pharmacological options available to reduce hyperglycaemia in DM, epidemiological studies suggest that glucose levels remain high in a substantial proportion of patients. This supports the need for additional strategies for the treatment of hyperglycaemia. SCOPE: This review focuses on the role of the kidney in glucose reabsorption and explores inhibition of renal glucose reabsorption as a novel approach to treat type 2 DM. A literature search to August 2008 using PubMed was used to compile data for review. Abstracts and presentations from the American Diabetes Association and the European Association for the Study of Diabetes, the American Society of Nephrology, and the International Society of Nephrology Annual Meetings were also searched for relevant studies. FINDINGS: Glucose filtered by the kidney is normally reabsorbed into the proximal renal tubule. Data from animal models suggest that approximately 90% of this reabsorption occurs through the sodium-coupled glucose cotransporter (SGLT) 2, which is a protein expressed almost exclusively in the proximal tubule of the kidney. Inhibition of SGLT2, and thus inhibition of renal glucose reabsorption, has the potential to reduce hyperglycaemia in patients with DM. Patients with familial renal glucosuria, a genetic disorder of SGLT2, do not appear to have adverse clinical consequences related to impaired renal reabsorption of glucose, which suggests that SGLT2 might be both an effective and safe treatment target for hyperglycaemia. In animal models of DM, pharmaceutical inhibition of SGLT2 reduces hyperglycaemia, and may improve insulin resistance. CONCLUSION: Reduction of renal glucose reabsorption is a novel approach to DM treatment that potentially provides improvements in glucose lowering. Various SGLT2 inhibitors are currently in development in human trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Relative or absolute deficiency of insulin and/or glucose promotes preferential metabolism of fats/triglycerides into glycerol and 3 fatty acids (via activation of adipocyte hormone sensitive lipase).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Increased free fatty acid delivery to the liver (mitochondrial oxidation) generates ketones (e.g., acetone, acetoacetone, and beta-hydroxybutyrate).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Mild ketosis due to carbohydrate restricted dietary ketosis may have favorable health effects (i.e., decreased hunger; treatment of epilepsy; fatty acids are the main fuel for the heart, which has little glycogen)”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“SGLT-2 inhibitors contribute to lower glucose levels, promote negative caloric balance, but do not increase insulin secretion”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Along with fasting, starvation, carbohydrate restricted diets, and poorly controlled type 1 diabetes mellitus, SGLT-2 inhibitors are associated with ketonemia”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 8×
“2009 Informa UK - Curr Med Res Opin 2009; 25(3) The kidney as a target in treating diabetes Bays 675”
BackgroundInfluentialIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Research works printed but not linked: 9
- Kosachunhanun N, 2006, J Med Assoc Thai, 89, S66
- Reaven GM, 2005, Panminerva Med, 47, 201
- Tsujihara K, 1996, I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo), 44, 1174
- Isaji M, 2007, Curr Opin Investig Drugs, 8, 285
- Glombik H, 2004, Chem Abstr, 140
- Washburn W, 2003, Chem Abstr, 138
- Komoroski B, 2009, Clin Pharmacol Ther
- Leslie B, 2008, American Society of Nephrology Renal Week
- Goudswaard AN, 2004, Cochrane Database Syst Rev
Cited by
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Self-citationSha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Schork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H.-U., Stefan, N., Fritsche, A., & Artunc, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 227
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 220
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217
Ten things to know about ten cardiovascular disease risk factors – 2022
Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 171
“[194] CVD outcomes trials in patients with T2DM support”
BackgroundSelf-citationWilding, J. P. H. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.018 · Cited by 168
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166
“These effects may reflect mild hemoconcentration secondary to the mild osmotic diuresis associated with increased UGE during canagliflozin treatment.”
BackgroundInfluentialSelf-citationBays, H. E. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0042-y · Cited by 121
Self-citationUPLC simultaneous determination of empagliflozin, linagliptin and metformin
Ayoub, B. M. (2015) · RSC Advances · doi:10.1039/c5ra17231d · Cited by 119
SGLT2 inhibitors: molecular design and potential differences in effect
Isaji, M. (2011) · Kidney International · doi:10.1038/ki.2010.511 · Cited by 112
Rosenthal, N., Meininger, G., Ways, K., Polidori, D., Desai, M., Qiu, R., Alba, M., Vercruysse, F., Balis, D., Shaw, W., et al. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12852 · Cited by 90
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Jung, C. H., Jang, J. E., & Park, J. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.261 · Cited by 96
Macdonald, F. R., Peel, J. E., Jones, H. B., Mayers, R. M., Westgate, L., Whaley, J. M., & Poucher, S. M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01291.x · Cited by 84
Grempler, R., Augustin, R., Froehner, S., Hildebrandt, T., Simon, E., Mark, M., & Eickelmann, P. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.12.027 · Cited by 89
Davies, M., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 75
Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
Yang, C., Chen, Y.-T., Wallace, C. G., Chen, K., Cheng, B., Sung, P., Li, Y., Ko, S., Chang, H., & Yip, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.095 · Cited by 83
Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
Bays, H. E., Bindlish, S., & Clayton, T. L. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100056 · Cited by 74
“…obesity and T2DM has heart failure, then beyond their indicated use as anti-diabetes medications, some sodium glucose transporter 2 inhibitors (SGLT1i) have clinical outcome data to support improvement in both CVD and heart failure [178], and may also facilitate mild weight reduction [179,180].”
BackgroundSelf-citationBays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73
Self-citationSha, S., Devineni, D., Ghosh, A., Polidori, D., Hompesch, M., Arnolds, S., Morrow, L., Spitzer, H., Demarest, K., & Rothenberg, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105638 · Cited by 72
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
“…Liver, pancreatic islets, kidney, and small intestine GLUT-4: Skeletal muscle, heart, and adipose tissue Sodium-linked active glucose transporters [108]: 6 isoforms (SGLT1-6) SGLT-1: Small intestine and kidney proximal tubule SGLT-2: Proximal tubule of the kidney Canagli fl ozin (SGLT2 inhibitor)…”
BackgroundInfluentialSelf-citationWhaley, J. M., Tirmenstein, M. A., Reilly, Poucher, Saye, Parikh, & List (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22503 · Cited by 68
Seufert, J. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s90662 · Cited by 65
Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review
Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100076 · Cited by 63
“In patients without diabetes mellitus, fi ltered glucose is typically reab-sorbed in renal tubules such that glucosuria only occurs when blood sugars exceed a variable threshold of around 180 mg/dL [23].”
BackgroundSelf-citationBays, H. E., Kothari, S. N., Azagury, D. E., Morton, J. M., Nguyen, N. T., Jones, P. H., Jacobson, T. A., Cohen, D. E., Orringer, C. E., Westman, E. C., et al. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.01.007 · Cited by 59
Self-citationHenschke, J. P., Lin, C., Wu, P., Tsao, W.-S., Liao, J., & Chiang, P. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00601 · Cited by 58
Thomas, L., Grempler, R., Eckhardt, M., Himmelsbach, F., Sauer, A., Klein, T., Eickelmann, P., & Mark, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01518.x · Cited by 50
Synthesis and SAR of Benzisothiazole- and Indolizine-β- d -glucopyranoside Inhibitors of SGLT2
Zhou, H., Danger, D. P., Dock, S. T., Hawley, L. B., Roller, S. G., Smith, C. D., & Handlon, A. L. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900010b · Cited by 55
Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?
Otto-Buczkowska, E., & Jainta, N. (2017) · Intern J Endocrinol Metab · doi:10.5812/ijem.13008 · Cited by 53
Effects of newly introduced antidiabetic drugs on autophagy
Ashrafizadeh, M., Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.028 · Cited by 51
Davidson, J. A., & Kuritzky, L. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2819 · Cited by 48
Sigafoos, J., Bowers, G. D., Castellino, S., Culp, A., Wagner, D. S., Reese, M. J., Humphreys, J. E., Hussey, E. K., Semmes, R. L. O., Kapur, A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047258 · Cited by 46
Sadurní, A., Kehr, G., Ahlqvist, M. M., Wernevik, J., Sjögren, H. P., Kankkonen, C., Knerr, L., & Gilmour, R. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201705373 · Cited by 46
Elkind-Hirsch, K. E., Seidemann, E. L., & Harris, R. (2020) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2020.100139 · Cited by 46
Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41
“SGLT2 inhibitors decrease body weight among patients with or without diabetes mellitus by 2% to 3%, largely because of a negative caloric balance as a result of glycosuria (5-9).”
BackgroundSelf-citationBays, H. E., Sartipy, P., Xu, J. L., Sjöström, C. D., & Underberg, J. A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.018 · Cited by 40
Self-citationTirmenstein, M. A., Dorr, T. E., Janovitz, E. B., Hagan, D. L., Abell, L. M., Onorato, J. M., Whaley, J. M., Graziano, M. J., & Reilly, T. P. (2013) · International Journal of Toxicology · doi:10.1177/1091581813505331 · Cited by 38
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
Candelario, N., & Wykretowicz, J. (2016) · Oxford Medical Case Reports · doi:10.1093/omcr/omw061 · Cited by 36
Dandona, P., & Chaudhuri, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12937 · Cited by 35
Provenzano, M., Pelle, M. C., Zaffina, I., Tassone, B., Pujia, R., Ricchio, M., Serra, R., Sciacqua, A., Michael, A., Andreucci, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.654557 · Cited by 34
Organo-zinc Promoted Diastereoselective C-Arylation of 1,2-Anhydrosugars from Arylboronic Acids
Tatina, M. B., Kusunuru, A. K., & Mukherjee, D. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b02364 · Cited by 33
Incretin Therapy – Present and Future
Garber, A. J. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.307 · Cited by 31
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
Henschke, J. P., Wu, P., Lin, C., Chen, S., Chiang, P., & HSIAO, C. ‐. (2015) · The Journal of Organic Chemistry · doi:10.1021/jo502839e · Cited by 30
The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes
Jaikumkao, K., Pongchaidecha, A., Chatsudthipong, V., Chattipakorn, S. C., Chattipakorn, N., & Lungkaphin, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.095 · Cited by 28
Seidu, S., Kunutsor, S. K., Topsever, P., & Khunti, K. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.303 · Cited by 25
Lullo, L. D., Mangano, M., Ronco, C., Bàrbera, V., Pascalis, A. D., Bellasi, A., Russo, D., Iorio, B. R. D., & Cozzolino, M. G. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.005 · Cited by 25
Tondt, J., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100017 · Cited by 24
“…“ -tides ” ) May decrease body weight [12 – 15] Sodium glucose co-transporter 2 inhibitors (e.g., “ - fl ozins ” ) May decrease body weight [12,15, 16] Alpha glucosidase inhibitors (e.g., acarbose, miglitol) May decrease body weight [12,13, 15] Amylin mimetic (pramlintide) May decrease body…”
BackgroundSelf-citationWhat's next after metformin? focus on sulphonylurea: add-on or combination therapy
Lim, P. C., & Chong, C. P. (2015) · Pharmacy Practice · doi:10.18549/pharmpract.2015.03.606 · Cited by 20
A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives
Han, Z., Ma, K., Tao, H., Liu, H., Zhang, J., Sai, X., Li, Y., Chi, M., Nian, Q., Song, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826732 · Cited by 21
Hrapchak, M. J., Latli, B., Wang, X., Lee, H., Campbell, S. J., Song, J. J., & Senanayake, C. H. (2014) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3240 · Cited by 21
Yue, X., Wang, J., Zhang, X.-R., Yang, J. H., Shan, C., Zheng, M.-Y., Ren, H.-Z., Zhang, Y., Yang, S.-H., Guo, Z.-H., et al. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.4.621 · Cited by 21
Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
Fukuda, M., Nabeta, M., Muta, T., Fukami, K., & Takasu, O. (2020) · International Journal of Emergency Medicine · doi:10.1186/s12245-020-0261-8 · Cited by 19
Staff, T. P. O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110069 · Cited by 17
Polli, J. W., & Humphreys, J. E. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000200 · Cited by 16
Duo, Y., Gao, J., Yuan, T., & Zhao, W. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13348 · Cited by 15
Pathan, M., & Kshirsagar, A. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00138 · Cited by 13
Kunutsor, S. K., Seidu, B. S., & Seidu, S. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.007 · Cited by 12
Wang, X., Sun, Z., Gao, Y., Liu, Q. S., Yang, X., Liang, J., Ren, J. L., Ren, Z., Zhou, Q., & Jiang, G. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.114979 · Cited by 12
Le rôle du rein dans l’homéostasie du glucose
Girard, J. R. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70491-7 · Cited by 12
Xiong, S., Huang, L., Liu, H., Zhang, X., Li, M., Cui, Y.-B., Shao, C., & Hu, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.97287 · Cited by 11
Coppenrath, V. A., & Hydery, T. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017731111 · Cited by 9
Second revolution in cardiovascular prevention
Chiang, C., Wang, K.-L., Cheng, H., Sung, S., & Chao, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000276 · Cited by 8
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line
Gupte, M., Umbarkar, P., & Lal, H. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6741-2 · Cited by 8
Mécanisme d’action des inhibiteurs du cotransporteur sodiumglucose de type 2 (SGLT2)
Girard, J. R. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30052-3 · Cited by 7
Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes
Brunton, S., & Reid, T. (2014) · Hospital Practice · doi:10.3810/hp.2014.08.1122 · Cited by 7
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
Chiang, C., Ueng, K., Chao, T., Lin, T., Wu, Y., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.08.003 · Cited by 7
“SGLT2 inhibitors blocked SGLT2 in the proximal tubule in the kidney (36), resulting in glucosuria, blood glucose lowering, and body weight loss (37).”
BackgroundZawadka, M., Taguiam, E., Lê, M., Sanjanwala, R., Liu, S., Shah, A. H., & Kunutsor, S. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70411 · Cited by 6
“82 GLP-1RAs enhance insulin secretion and suppress glucagon in a glucose-dependent manner, while also contributing to weight loss, improved endothelial function, and reduced inflammation.”
Yii, E. S. S., Azli, A. W., & Sitaram, P. N. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03232-3 · Cited by 6
Perin, P. C., & Fornengo, P. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0677-5 · Cited by 6
“first isolated from the root bark of apple trees and the first available oral agent is dapagliflozin [14].”
BackgroundKhodabandeh, H., Bakhshizade, Z., Taklif, M. H., Fakhrabadi, H. Z., Alivand, S., Alivand, N., Rashidizadeh, G., Jampour, L., & Shirani, M. (2023) · Journal of Nephropathology · doi:10.34172/jnp.2023.21477 · Cited by 5
Mishra, S. K., Singh, A., Mishra, N., Pandey, H., & Tiwari, V. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809450-1.00005-3 · Cited by 5
Seidu, S., Kunutsor, S. K., Taguiam, E., & Khunti, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70728 · Cited by 4
Sukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Bebernitz, G. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12430-8 · Cited by 4
Liu, H., Zhang, X., Cui, Y., Xiong, S., Huang, L., Li, M., Shao, C., & Hu, X. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5842 · Cited by 3
Kidneys function in glucose homeostasis regulation and its therapeutic implications
Otto-Buczkowska, E., & Tucholski, K. (2013) · Family Medicine & Primary Care Review · Cited by 3
Green quantitative methods for linagliptin and empagliflozin in dosage forms
Fraihat, S. M. (2024) · Green Processing and Synthesis · doi:10.1515/gps-2023-0228 · Cited by 2
“It inhibits the sodium-glucose co-transporter-2 (SGLT-2) and was approved to treat type 2 diabetes [2].”
BackgroundEmpagliflozin and metformin combination therapy in Type 2 diabetes mellitus
Jeyalalitha, R. (2015) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20151382 · Cited by 2
Sodium Glucose Cotransporter-2 Inhibitors: An Overview from Evolution to Clinical Implications
Ravi, R., Balasubramaniam, V., Dhingra, S., Murti, K., & Ponnusankar, S. (2024) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1292 · Cited by 1
THE FUTURE OF TYPE 2 DIABETES MANAGEMENT: PREVENTION, EARLY INTERVENTION, AND PIPELINE MEDICATIONS *
White, J. R. (2009) · Cited by 1
Regulation of renal brush-border glucose transport in response to metabolic dysregulation
Chichger, H. (2011) · UCL Discovery (University College London)
Sodium glucose transporters inhibitors in the management of heart failure
Singh, R. B., Chakravorty, S., Elmaraghi, O., Nabavizadeh, F., Elkilany, G. N., Jain, M., Shukla, A. K., Agarwal, A., Yaduvanshi, A., Mahajan, S., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00036-5
Cozzolino, M. G., & Bellasi, A. (2017) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)
Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use
Arslanian, S. A., Barrett, T. G., & Shehadeh, N. (2026) · Pediatric Diabetes · doi:10.1155/pedi/4555805
“An overview of the mechanism of action of SGLT-2 inhibitors is provided in Figure 1 SGLT-2 is predominantly expressed in the proximal convoluted tubule and is responsible for ~90 % of renal glucose reabsorption [64].”
Metadata
- Authors
- Bays, H.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Corresponding author
- Bays, Harold
- ORCID
- Bays, Harold
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2009-01-28
- Volume
- 25
- Issue
- 3
- Pages
- 671-681
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2154020052
- Cited by
- 83
- References
- 56
- Citations by year
- 2026: 3 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 9 · 2016: 5 · 2015: 9 · 2014: 7 · 2013: 5 · 2012: 5
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- SGLT2 inhibitors, type 2 diabetes, renal glucose reabsorption, hyperglycemia, proximal tubule, insulin resistance, glucose-lowering therapy
- MeSH terms
- Diabetes Mellitus, Glucose, Humans, Kidney, Monosaccharide Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.